Hypomagnesemia and Its Clinical Outcome

Co-relation of Hypomagnesemia With Clinical Outcomes in Critically Ill Patients Admitted to a Tertiary Care ICU in Bangladesh

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07089004

Acronym

Hypogamnesamia

Enrollment

112

Registered

2025-07-28

Start date

2024-06-01

Completion date

2025-04-25

Last updated

2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Hypomagnesemia, Intensive Care Unit (ICU) Patients, Scoring Systems

Brief summary

Magnesium is an essential electrolyte involved in numerous physiological processes, including maintaining cellular integrity, regulating muscle tone, supporting cardiovascular function, and modulating immune responses. Despite its critical role, magnesium is often overlooked in clinical practice, earning it the title of the forgotten electrolyte. Hypomagnesemia, defined as serum magnesium levels below 1.5 mEq/L, has been associated with adverse clinical outcomes such as increased mortality, prolonged ICU stays, and higher requirements for mechanical ventilation. Critically ill patients are particularly vulnerable to hypomagnesemia due to various underlying conditions, gastrointestinal losses, and renal complications. However, limited data are available from Bangladesh on the burden and clinical impact of hypomagnesemia in ICU settings. This study aims to assess the correlation between hypomagnesemia and clinical outcomes, including length of ICU stay, need for mechanical ventilation, and mortality among critically ill patients in a tertiary care ICU in Bangladesh.

Interventions

DIAGNOSTIC_TESTNo intervention (observational study)

Observational - Biochemical, Hematological and Clinical Scoring Assessments

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients aged 18 years and above. * Patients admitted to the Intensive Care Unit (ICU). * Patients who have serum magnesium levels measured within 24 hours of ICU admission.

Exclusion criteria

* Patients with known end-stage renal disease on dialysis. * Patients with a history of magnesium supplementation prior to ICU admission. * Pregnant women. * Patients with incomplete medical records or unavailable laboratory data.

Design outcomes

Primary

Measure	Time frame	Description
Association of Hypomagnesemia with ICU Mortality	From the date of ICU admission until the date of ICU discharge or death, assessed up to 60 days.	To assess the relationship between low serum magnesium levels and all-cause mortality among critically ill ICU patients.

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026